Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid

Transplant Infectious Disease

Volumn 18, Issue 1, 2016, Pages 79-88

  Radtke, J ^a   Dietze, N ^a   Spetzler, V N ^a   Fischer, L ^a   Achilles, E G ^a   Li, J ^a   Scheidat, S ^a   Thaiss, F ^a   Nashan, B ^a   Koch, M ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

CMV prophylaxis; Cytomegalovirus; Everolimus; Immunosuppression; Kidney transplantation; mTOR inhibitors

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; RITUXIMAB; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; TARGET OF RAPAMYCIN KINASE;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY ALLOGRAFT; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PLASMAPHERESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK FACTOR; AGED; ANTAGONISTS AND INHIBITORS; CYTOMEGALOVIRUS; DRUG EFFECTS; GRAFT REJECTION; ISOLATION AND PURIFICATION; KIDNEY TRANSPLANTATION; MIDDLE AGED; VIROLOGY;

ADULT; AGED; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EVEROLIMUS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; TOR SERINE-THREONINE KINASES;

EID: 84958598330     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12494     Document Type: Article

References (38)

1. Nett P, Heisey D, Fernandez L, Sollinger H, Pirsch J. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation 2004; 78 (7): 1036-1041.
2. Kanter J, Pallardó L, Gavela E, et al. Cytomegalovirus infection renal transplant recipients: risk factors and outcome. Transplant Proc 2009; 41 (6): 2156-2158.
3. Helanterä I, Schachtner T, Hinrichs C, et al. Current characteristics and outcome of cytomegalovirus infections after kidney transplantation. Transpl Infect Dis 2014; 16 (4): 568-577.
4. Tedesco Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10 (6): 1401-1413.
5. Brennan DC, Aguado JM, Potena L, et al. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. Rev Med Virol 2013; 23 (2): 97-125.
6. Clippinger AJ, Maguire TG, Alwine JC. The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection. J Virol 2011; 85 (8): 3930-3939.
7. Poglitsch M, Weichhart T, Hecking M, et al. CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages. Am J Transplant 2012; 12 (6): 1458-1468.
8. + T-cell response compared with cyclosporine- or mycophenolate-treated patients. Transplantation 2013; 95 (1): 184-191.
9. Büchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving Thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7 (11): 2522-2531.
10. Glotz D, Charpentier B, Abramovicz D, et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 2010; 89 (12): 1511-1517.
11. Fortun J, Martin-Davila P, Pascual J, et al.; RESITRA Transplant Network. Immunosuppressive therapy and infection after kidney transplantation. Transpl Infect Dis 2010; 12 (5): 397-405.
12. Guba M, Pratschke J, Hugo C, et al.; SMART-Study Group. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36 months after transplantation. Transpl Int 2012; 25 (4): 416-423.
13. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002; 11 (12): 1845-1857.
14. Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit 2002; 24 (1): 53-58.
15. Kobashigawa J, Ross H, Bara C, et al. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. Transpl Infect Dis 2013; 15 (2): 150-162.
16. Ghassemieh B, Ahya VN, Baz MA, et al. Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation. J Heart Lung Transplant 2013; 32 (7): 701-706.
17. Rittà M, Costa C, Solidoro P, et al. Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection. Antiviral Res 2015; 113: 19-26.
18. Tedesco-Silva H, Felipe C, Ferreira A, et al. Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses. Am J Transplant 2015; 15 (10): 2655-2664.
19. Budde K, Becker T, Arns W, et al.; ZEUS Study Investigators. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011; 377 (9768): 837-847.
20. Budde K, Lehner F, Sommerer C, et al.; ZEUS Study Investigators. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. Am J Transplant 2015; 15 (1): 119-128.
21. Chadban SJ, Eris JM, Kanellis J, et al.; SOCRATES Study Group. A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients. Transpl Int 2014; 27 (3): 302-311.
22. Vítko Š, Margreiter R, Weimar W, et al.; RAD B201 Study Group. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5 (10): 2521-2540 [erratum 2006; 6 (1): 243.].
23. Lorber MI, Mulgaonkar S, Butt KM, et al.; B251 Study Group. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005; 80 (2): 244-252.
24. Jassal SV, Roscoe JM, Zaltzman JS, et al. Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. J Am Soc Nephrol 1998; 9 (9): 1697-1708.
25. Strippoli GF, Hodson EM, Jones C, Craig JC. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006; 81 (2): 139-145.
26. Kotton CN, Kumar D, Caliendo AM, et al.; Transplantation Society International CMV Consensus Group. Updated international consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2013; 96 (4): 333-360.
27. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007; 165 (6): 710-718.
28. Andrassy J, Hoffmann VS, Rentsch M, et al. Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? A systematic review and meta-analysis Transplantation 2012; 94 (12): 1208-1217.
29. Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012; 93 (11): 1075-1085.
30. Moorman NJ, Shenk T. Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication. J Virol 2010; 84 (10): 5260-5269.
31. Schroeder R, Michelon T, Fagundes I, et al. Cytomegalovirus disease latent and active infection rates during the first trimester after kidney transplantation. Transplant Proc 2004; 36 (4): 896-898.
32. Yang J, Wang J, Men T, et al. Comparison of clinical outcome of low-dose and high-dose rabbit antithymocyte globulin induction therapy in renal transplantation: a single-center experience. Ann Transplant 2014; 19: 277-282.
33. Helanterä I, Koskinen P, Finne P, et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int 2006; 19 (11): 893-900.
34. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8 (5): 975-983.
35. Smedbråten YV, Sagedal S, Leivestad T, et al. The impact of early cytomegalovirus infection after kidney transplantation on long-term graft and patient survival. Clin Transplant 2014; 28 (1): 120-126.
36. Harvala H, Stewart C, Muller K, et al. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol 2013; 85 (5): 893-898.
37. Meije Y, Fortún J, Len Ó, et al.; on behalf of Spanish Network for Research on Infection in Transplantation (RESITRA) and the Spanish Network for Research on Infectious Diseases (REIPI). Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort. Transpl Infect Dis 2014; 16 (3): 387-396.
38. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3): S1-S115.